---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-008677"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:12:21.142206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma FY2022 net loss $93.9M; WHIM trial success, NDA submission planned for H2 2023

## Summary
- Cash $123M as of Dec 31, 2022; funds operations into Q2 2024.
- Phase 3 4WHIM trial met primary and key secondary endpoints; NDA submission expected early 2H 2023.
- Phase 2 chronic neutropenia trial enrolling; data and regulatory path clarity expected 2Q/3Q 2023.
- Gross proceeds ~$120M from two 2022 financings; amended Hercules loan lowered cash covenant to $20M.

## SEC filing metadata
- accession: 0001628280-23-008677
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/0001628280-23-008677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/xfor-20230321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-008677
- JSON: https://secwatch.observer/filing/0001628280-23-008677.json
- Plain text: https://secwatch.observer/filing/0001628280-23-008677.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 21, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828023008677/0001628280-23-008677-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.